Elise Weerts
@EliseWeertsPhD
Professor, @HopkinsMedicine @jhucsl Behavioral Pharmacologist and Neuroscientist; Views/Posts are my own; She/Her
Congratulations to Drs. Tory Spindle and Austin Zamarripa @zamster13 for winning highly competitive awards from the @APA. Tory is the APA Division 28 Young Psychopharmacologist Award winner and Austin is the APA Division 28 Outstanding Dissertation Award winner for 2023! 🥳🎉
sciencedirect.com/science/articl… New paper from our lab with @BryanJenkinsPhD and @CassieMoorePhD CBD interactions with THC may not be what you expect
Amazing work by DBB's @BryanJenkinsPhD on summarizing the effects of prenatal cannabinoids on the brain and behavior! Online today - in NBBR @EliseWeertsPhD sciencedirect.com/science/articl…
One of my favorite aspects of science is getting to play in the sandbox with friends & colleagues and seeing the integration of different research streams come together. I am very privileged to have gotten to go on this scientific journey with @sjo09 @SLLesuis and @Franklandlab
Excited to share our new results! We (huge team effort led by post-doc extraordinaire @SLLesuis) examined the effects of acute stress on threat memory generalization and engram ensemble architecture. sciencedirect.com/science/articl…
Just in case - started on #Bluesky You can find me @ EliseWeerts.Bsky.social Let’s see how it goes.
Klaus Miczek was a giant of Psychopharmacology: the field and the journal. R.I.P. Here's an interview from 2022. He covers his transformative impact on the journal, evolution of the field, @PsychopharmEBPS v @npp_journal, writing/editing success, & more. youtu.be/PlUUZ8olWEY?si…
Excited to share our new results! We (huge team effort led by post-doc extraordinaire @SLLesuis) examined the effects of acute stress on threat memory generalization and engram ensemble architecture. sciencedirect.com/science/articl…
This shook me today. Klaus was my graduate school mentor for my Masters degree and my PhD. He had the biggest impact on my scientific development than anyone else. Thank you, Klaus, and may you rest in greatness.
Excited to share our new results! We (huge team effort led by post-doc extraordinaire @SLLesuis) examined the effects of acute stress on threat memory generalization and engram ensemble architecture. sciencedirect.com/science/articl…
Early career faculty members- apply now to be an editorial fellow for @ECP_editor for the 2024 year! Learn more about the editorial process and earn an honorarium. Applications are open here or below until Dec 1! tinyurl.com/ECPeditorialfe…
Please attend our 9/15/2023 @CureAddNowOrg forum on #SUDs featuring my impressive colleagues @ceciliabergeria and @CassieGipson3 among others. We'll discuss #xylazine, #craving, #fentanyl, #overdose and more. Registration is free! cureaddictionnow.org/forum/
New review with some of my favorite people @MegHaneyPhD @HillardCece @drdebah @haleyv on current state of endocannabinoid based therapeutics in the context of psychiatric illlness, with a focus on substance use disorders, trauma-related disorders and ASD. cambridge.org/core/product/i…
In case you missed it - High dose CBD can affect other commonly used medications people take. See our Open access paper on Cytochrome P450‐Mediated Cannabinoid‐Drug Interactions in Healthy Adult Participants - Wiley Online Library ascpt.onlinelibrary.wiley.com/doi/10.1002/cp…
As a follow up to our paper showing important PK/PD interactions between high dose CBD and THC - it’s all about the CYPs
Understanding cannabis-drug interactions is critical. Check out our new paper that expands on dose adjustment of drugs co-consumed with cannabis products and the dose of CBD in cannabis products to reduce interaction risk with Δ9-THC. ascpt.onlinelibrary.wiley.com/doi/10.1002/cp…
I have tested the effects of a lot of medications for their potential to treat Cannabis Use Disorder and AEF0117 shows the most promise by far. This has been an exciting journey!
We are thrilled to share the 1st publication in @NatureMedicine of our new pharmacological class, the CB1-SSi, and of the phase 2a clinical trial for cannabis use disorders (CUD), in collaboration with @ColumbiaPsych ✅ $AELIS #AELIS #columbiamed #clinicaltrials
A new paper from our postdoctorate fellow Dr. Ashley Dowd discusses the results of a cross-sectional survey (n=370) inquiring about patterns of use for those who consume oral cannabis products. sciencedirect.com/science/articl… We found that:
Colleagues, please see and share this paper on #fentanyl absorption, distribution, metabolism, and excretion. The take-home is that fentanyl is so lipophilic it is sequestered peripherally into muscle and fat 1/3 journals.lww.com/journaladdicti…
We just published the largest systematic review of control conditions in randomized psychedelic trials! We looked at 126 articles from 1963-2020, encompassing 86 unique studies. Here's a summary, w @mkbradley_ @Drug_Researcher, others not on twitter 1/ psychiatrist.com/jcp/psychophar…